BioCentury
ARTICLE | Company News

BMS to acquire Flexus for up to $1.3B

February 24, 2015 2:31 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) will acquire cancer immunotherapy play Flexus Biosciences Inc. (San Carlos, Calif.) for $800 million up front.

BMS will receive Flexus' F001287, a preclinical small molecule inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1), and its discovery platform for IDO and tryptophan 2,3-dioxygenase ( TDO2) ( TDO) inhibitors. Flexus shareholders are eligible for up to another $450 million in development milestones. ...